105 related articles for article (PubMed ID: 31837958)
41. Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.
Iankov ID; Kurokawa CB; D'Assoro AB; Ingle JN; Domingo-Musibay E; Allen C; Crosby CM; Nair AA; Liu MC; Aderca I; Federspiel MJ; Galanis E
Cancer Gene Ther; 2015 Sep; 22(9):438-44. PubMed ID: 26272026
[TBL] [Abstract][Full Text] [Related]
42. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
43. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
44. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
[TBL] [Abstract][Full Text] [Related]
45. Aurora kinase inhibition as an anticancer strategy.
Hilton JF; Shapiro GI
J Clin Oncol; 2014 Jan; 32(1):57-9. PubMed ID: 24043748
[No Abstract] [Full Text] [Related]
46. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
[No Abstract] [Full Text] [Related]
47. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
[TBL] [Abstract][Full Text] [Related]
48. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
49. Pazopanib for advanced liposarcoma.
Gilbert JA
Lancet Oncol; 2017 Oct; 18(10):e564. PubMed ID: 28844815
[No Abstract] [Full Text] [Related]
50. Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
Hotta K; Kiura K; Takigawa N; Matsuo K; Tabata M; Fujiwara Y; Tanimoto M
J Clin Oncol; 2008 Dec; 26(35):5826-7; author reply 5827. PubMed ID: 19001344
[No Abstract] [Full Text] [Related]
51. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
Piccaluga PP; Malagola M; Rondoni M; Arpinati M; Paolini S; Candoni A; Fanin R; Messa E; Pirrotta MT; Lauria F; Visani G; Alberti D; Rancati F; Vinaccia V; Russo D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Dec; 92(12):1721-2. PubMed ID: 18056005
[TBL] [Abstract][Full Text] [Related]
52. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
53. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
54. Kinase inhibitors for refractory thyroid cancers.
Schlumberger M
Lancet Oncol; 2010 Oct; 11(10):912-3. PubMed ID: 20851683
[No Abstract] [Full Text] [Related]
55. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
56. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
57. Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib.
Védy D; Muehlematter D; Rausch T; Stalder M; Jotterand M; Spertini O
J Clin Oncol; 2010 Jan; 28(3):e33-5. PubMed ID: 19901109
[No Abstract] [Full Text] [Related]
58. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
59. 57th American Society of Hematology Annual Meeting.
Smith LL
Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
[No Abstract] [Full Text] [Related]
60. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
